朱翻译
我写的双语小说《好运的代价》The Cost of Fortune辉瑞生物。正是他所在基金密切关注、处于深度尽调阶段的那家濒临破产的生物科技公司。FH-209，是他们孤注一掷的阿尔茨海默病改良药。成功，公司估值能翻百倍。失败，将直接归零。而这份最终数据…是他们评估中最关键、也是最缺失的一环！公司以“商业机密”和“学术发表流程”为由，一直拒绝提供完整数据，只给了些模糊的正面趋势图。Hyfei Bio. The very bankrupt biotech firm his fund was closely monitoring, in deep due diligence. FH-209 was their desperate, last-ditch Alzheimer's drug candidate—a modified therapy. Success would mean a hundred-fold increase in valuation. Failure would mean total loss. This final dataset was the most critical piece still missing from their evaluation. The company had consistently refused to share the full data, citing "trade secrets" and the "academic publication process," offering only vague trend charts with positive spin.
发布于 江苏
1
评论
赞
未登录
友善发言
评论
加载中
